Sam Altman's longevity startup is upping the dose in an Alzheimer's drug trial after a lackluster first round
The Sam Altman-backed longevity biotech company is upping the dose of its experimental Alzheimer's drug in clinical trials.
Retro Biosciences, a longevity biotech company backed by Sam Altman, is increasing the dosage of an Alzheimer's drug trial after initial results were underwhelming. The company is adding 42% more participants to their Phase 1 trial, bringing the total number of volunteers from 76 to 108. The drug, RTR 242, works by stimulating key cellular recycling processes in the body, which deteriorate as we age and become more pronounced in neurodegenerative diseases such as Alzheimer's and Parkinson's.
While no major side effects have been detected in healthy volunteers, Retro Biosciences faces the challenge of determining the optimal dose that balances potency and side effects.
Written by urgent.news from Business Insider's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
